Gail M. Farfel, Ph.D.

Gail M. Farfel, Ph.D. has served on our Board of Directors since April 2019.  Dr. Farfel was most recently Chief Executive Officer of ProMIS Neurosciences Inc., a biotechnology company focused antibody therapeutics for neurodegenerative diseases. Previously Dr. Farfel held senior leadership positions at Zogenix, Inc., a pediatric rare disease company;  Marinus Pharmaceuticals Inc., a biopharma engaged in development of treatment for neurological disorders; and Novartis Pharmaceuticals Corporation, where she served as Vice President and Therapeutic Area Head for Neuroscience.  Dr. Farfel began her career in pharmaceutical drug development at Pfizer Inc., where she worked in Clinical Development and Global Medical Affairs, directing programs through all stages of clinical development and regulatory submissions. Additionally, Dr. Farfel has served on the board of directors of AVROBIO, Inc. since October 2020. Dr. Farfel is the author of over 50 scientific articles and presentations in the areas of neuropsychopharmacology and drug effects and is a Director on the Board of the American Society for Experimental Neurotherapeutics.  She holds a Ph.D. in Neuropsychopharmacology from the University of Chicago, where she is a Director on the Alumni Board. Dr. Farfel also holds a bachelor’s degree in Biochemistry from the University of Virginia.